Human placental lactogen is a first-trimester maternal serum marker of Down syndrome

2006 ◽  
Vol 27 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Michael Christiansen ◽  
Tina Lindvig Sørensen ◽  
Bent Nørgaard-Pedersen
2003 ◽  
Vol 49 (9) ◽  
pp. 1445-1449 ◽  
Author(s):  
Cees B M Oudejans ◽  
Attie T J J Go ◽  
Allerdien Visser ◽  
Monique A M Mulders ◽  
Bart A Westerman ◽  
...  

Abstract Background: mRNA of placental origin (i.e., human placental lactogen and β-human chorionic gonadotropin) has been demonstrated to be easily detectable in maternal plasma. We tested whether detection of chromosome 21-encoded mRNA of placental origin is possible in maternal plasma obtained during the first trimester. Methods: Plasma samples were obtained from pregnant women between weeks 9–13 of pregnancy. RNA was isolated from 800 or 1600 μL of plasma by silica-based affinity isolation and, after on-column DNase treatment, was subjected to two-step, one-tube reverse transcription-PCR with gene specific primers. Results: Three chromosome 21-encoded genes located within the Down syndrome critical region with overexpression in trisomy 21 placentas were screened for expression in early placental tissue to select their potential use for RNA based plasma screening. One of the chromosome 21-encoded genes (LOC90625) showed strong expression in first trimester placenta similar to CSH1 (human placental lactogen) and was selected for plasma analysis. The RNA isolation assay was validated with CSH1 mRNA, which could be detected in the plasma of all women tested in weeks 9–13 of pregnancy. RNA from the chromosome 21-encoded, placentally expressed gene, LOC90625, was present in maternal first-trimester plasma and could be detected in 60% of maternal plasma samples when 800 μL of plasma was used and in 100% of samples when 1600 μL of plasma was used. Conclusion: The detection of chromosome 21-encoded mRNA of placental origin in maternal plasma during the first trimester may allow development of plasma-RNA-based strategies for prenatal prediction of Down syndrome. LOC90625 is a candidate gene for this purpose.


2006 ◽  
Vol 26 (10) ◽  
pp. 973-979 ◽  
Author(s):  
Jennie Laigaard ◽  
Kevin Spencer ◽  
Michael Christiansen ◽  
Nicholas J. Cowans ◽  
Severin Olesen Larsen ◽  
...  

2018 ◽  
Vol 34 (3) ◽  
pp. 318-323
Author(s):  
Indranil Ghoshal ◽  
Varashree Bolar Suryakanth ◽  
Vijetha Shenoy Belle ◽  
Krishnananda Prabhu

2003 ◽  
Vol 23 (13) ◽  
pp. 1086-1091 ◽  
Author(s):  
Jennie Laigaard ◽  
Tina Sørensen ◽  
Camilla Fröhlich ◽  
Bent Nørgaard Pedersen ◽  
Michael Christiansen ◽  
...  

1999 ◽  
Vol 19 (10) ◽  
pp. 905-910 ◽  
Author(s):  
Michael Christiansen ◽  
Claus Oxvig ◽  
Jill M. Wagner ◽  
Qiu-Ping Qin ◽  
Tri H. Nguyen ◽  
...  

2007 ◽  
Vol 30 (4) ◽  
pp. 543-544
Author(s):  
M. Ryynanen ◽  
Y. Valinen ◽  
J. Ignatius ◽  
P. Laitinen ◽  
T. Ahola ◽  
...  

2020 ◽  
Author(s):  
AYSE OZBAN

Abstract Objective: This study aims to determine whether it is possible to predict preeclampsia by comparing postpartum results and test results of the pregnant women diagnosed with preeclampsia, whose first and/or second trimester screening tests were accessible, and to demonstrate the predictability of severity and week of onset.Background: 204 patients underwent renal transplantation in our center and 84 of them were female. Five of our patients (one of them had two births) gave birth to a total of 6 pregnancies.Method: 135 patients were diagnosed with preeclampsia and their first and/or second trimester screening tests were accessible, and 366 control participants gave birth to a healthy baby between 37-41 weeks after standard follow-up period for pregnancy and their screening tests were also accessible.Results: The study results show that the first trimester maternal serum PAPP-A level is significantly low in preeclamptic pregnant women, and that the second trimester maternal serum AFP and hCG levels are significantly high and uE3 levels are significantly low The results also suggest that the first and second trimester Down syndrome biochemical markers can be used in preeclampsia screening.Conclusion: Among these markers, uE3 is the parameter which affects the possibility of preeclampsia the most. However, the first and second trimester Down syndrome biochemical markers are not effective in predicting the severity and onset week of preeclampsia.


Author(s):  
Mónica Echevarria ◽  
Carmen Comas ◽  
M Angeles Rodríguez ◽  
Joan Nicolau ◽  
Bernat Serra ◽  
...  

ABSTRACT Objective To estimate the improvement in screening efficiency when ductus venosus (DV) Doppler studies are added to existing Down syndrome (DS) screening protocols. Methods First-trimester combined screening for trisomy 21 was prospectively carried out, from October 2003 to March 2008, in 8842 consecutive singleton pregnancies attended in our tertiary reference center. The nuchal translucency (NT) and the pulsatility index for veins for DV were calculated. The maternal serum biochemistry was measured using the Kryptor analyzer, at the same time of the scan (one step strategy) or before it (two step strategy). The detection rate (DR) and false-positive rates for standard screening strategy (maternal age, NT and biochemistry) and the same strategy but including DV assessment were calculated. Results Successful DV assessment was possible in the 95.3% of cases, representing a total of 8426 cases. Down syndrome was identified in 34 pregnancies (prevalence of DS 1:250). For a fixed screen positive rate of 5%, the addition of the DV assessment improves the DR from 85 to 94% and, for a fixed DR of 85%, it reduces the number of unnecessary invasive tests from 3.7 to 3.2%. Conclusion Early evaluation of DV can be introduced to standard DS screening strategies in experienced centers as a first level test to reduce invasive test rate derived from the existing protocols.


2017 ◽  
Vol 31 (21) ◽  
pp. 2847-2851 ◽  
Author(s):  
Thitikarn Lerthiranwong ◽  
Chanane Wanapirak ◽  
Supatra Sirichotiyakul ◽  
Fuanglada Tongprasert ◽  
Kasemsri Srisupundit ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document